National consumer drug safety network launched UK rejects compulsory mental health treatment
Page 1 Citing the recent withdrawal of refecoxib (Vioxx), members of a new national consumer …

Published at www. cmaj. ca on Sept. 30, 2004. whether the increased risk applies only to
rofecoxib or to all COX-2 inhibitors.“I really think the regulatory agencies should ask all COX …

Institute of Medicine's new drug safety report: implications for Canada the FDA needs better
resources to carry out its drug review and surveillance functions. Among the …

This article focuses on the United States Food and Drugs Administration's (FDA) drug safety
initiative. John K. Jenkins, director of FDA's Office of New Drugs, maintained that regulators …

The recent withdrawal of rofecoxib (Vioxx) from the worldwide market has focused intense
public scrutiny on drug safety. Although the US Food and Drug Administration monitors drug …

Improving drug safety through legislation and independent research the Hippocratic oath
extols physi cians “to first do no harm.” So, doctors weigh the risks of using a drug …

On May 21, 1999, Merck was granted approval by the Food and Drug Administration (FDA)
to market rofecoxib (Vioxx). On September 30, 2004, after more than 80 million patients had …

The worldwide withdrawal of rofecoxib (Vioxx) marked the end of an era of relative
consumer innocence. It demonstrated unequivocally that, unlike other consumer “goods,” …

This paper analyzes the twelve-month period between August 2000 and August 2001 during
which Merck & Co. launched an aggressive marketing campaign for its new anti …

/1 2 therapy in 2006 are for the 7.5 mg tablet, with an average of 1.35 tablets per day. 11 The
average actual MCO cost for celecoxib was $113 per 30-day supply in early 2006 (an …